Longer-Term DME Data Bolster Optimism Around Mechanism For Unity’s UBX1325

The company announced 48-week, Phase IIa data for the drug in diabetic macular edema, an update from 24-week data the company announced in November.

Unity announced Phase IIa follow-up data in diabetic macular edema for UBX1325 • Source: Shutterstock

UNITY Biotechnology, Inc. got further proof-of-concept results for the mechanism of action of UBX1325 as it unveiled data showing the drug is effective in diabetic macular edema (DME), despite earlier data showing the drug failed in wet age-related macular degeneration (AMD).

The company announced 48-week data on 24 April from the Phase IIa BEHOLD study in patients receiving a single dose of UBX1325 and for whom treatment with anti-VEGF drugs had...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D